Moderna is a biotechnology business based in the US. Moderna stocks (MRNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $206.07 – an increase of 11.38% over the previous week. Moderna employs 1,300 staff and has a trailing 12-month revenue of around $2.7 billion.
How to buy Moderna stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: MRNA in this case.
- Research Moderna stocks. The platform should provide the latest information available.
- Buy your Moderna stocks. It's that simple.
What's in this guide?
- Can I buy shares in Moderna?
- Has coronavirus impacted Moderna shares?
- Moderna shares summary
- Compare share dealing platforms
- Is Moderna stock a buy or sell?
- Moderna performance over time
- Can I short Moderna shares?
- Are Moderna shares over-valued?
- Moderna's financials
- How volatile are Moderna shares?
- Does Moderna pay a dividend?
- Other common questions
How has Coronavirus impacted Moderna's stock price?
Since the stock market crash in March caused by coronavirus, Moderna's stock price has had significant positive movement.
Its last market close was $206.07, which is 91.15% up on its pre-crash value of $18.23 and 1,050.59% up on the lowest point reached during the March crash when the stocks fell as low as $17.91.
If you had bought $1,000 worth of Moderna stocks at the start of February 2020, those stocks would have been worth $1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $10,111.85.
Moderna stock priceUse our graph to track the performance of MRNA stocks over time.
Moderna stocks at a glance
|Latest market close||$206.07|
|52-week range||$54.21 - $227.71|
|50-day moving average||$175.414|
|200-day moving average||$151.0552|
|Wall St. target price||$181.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.492|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Moderna stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Moderna price performance over time
|1 week (2021-06-02)||7.55%|
|1 month (2021-05-13)||37.50%|
|3 months (2021-03-12)||50.43%|
|6 months (2020-12-11)||31.31%|
|1 year (2020-06-12)||232.37%|
|2 years (2019-06-13)||1,175.19%|
Is Moderna under- or over-valued?
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's P/E ratio
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 142x. In other words, Moderna stocks trade at around 142x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$673.1 million.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.7 billion|
|Operating margin TTM||23.2%|
|Gross profit TTM||USD$-574,877,000|
|Return on assets TTM||5.37%|
|Return on equity TTM||21.83%|
|Market capitalisation||USD$85.3 billion|
TTM: trailing 12 months
How to short and sell Moderna stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "MRNA.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 11.8 million Moderna stocks held short by investors – that's known as Moderna's "short interest". This figure is 0.9% down from 11.9 million last month.
There are a few different ways that this level of interest in shorting Moderna stocks can be evaluated.
Moderna's "short interest ratio" (SIR)
Moderna's "short interest ratio" (SIR) is the quantity of Moderna stocks currently shorted divided by the average quantity of Moderna stocks traded daily (recently around 9.3 million). Moderna's SIR currently stands at 1.27. In other words for every 100,000 Moderna stocks traded daily on the market, roughly 1270 stocks are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna stocks, or, against the total number of tradable Moderna stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding stocks (for every 100,000 Moderna stocks in existence, roughly 30 stocks are currently held short) or 0.0403% of the tradable stocks (for every 100,000 tradable Moderna stocks, roughly 40 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
Moderna stock dividends
We're not expecting Moderna to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Moderna stock price volatility
Over the last 12 months, Moderna's stocks have ranged in value from as little as $54.21 up to $227.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4708. This would suggest that Moderna's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
More on investing
Impact investing is perhaps the purest form of responsible investing. Want to know why? Read our guide to find out.Read more…
Find out what a short squeeze is and how to trade a short squeeze. We’ve detailed how they work, some examples and the high risks involved.Read more…
This guide discusses the ways that you can invest in platinum, either in physical form or on the stock market.Read more…
More guides on Finder
How to buy SSR Mining stock in Canada | $17.76
Steps to owning and managing SSRM, with 24-hour and historical pricing before you buy.
How to buy Miller Industries stock in Canada | $41.82
Steps to owning and managing MLR, with 24-hour and historical pricing before you buy.
How to buy Global Blood Therapeutics stock in Canada | $40.64
Steps to owning and managing GBT, with 24-hour and historical pricing before you buy.
How to buy Caleres stock in Canada | $27.91
Steps to owning and managing CAL, with 24-hour and historical pricing before you buy.
How to buy Axsome Therapeutics stock in Canada | $66.39
Steps to owning and managing AXSM, with 24-hour and historical pricing before you buy.
How to buy Raymond James Financial stock in Canada | $131.10
Steps to owning and managing RJF, with 24-hour and historical pricing before you buy.
How to buy Progyny stock in Canada | $63.98
Steps to owning and managing PGNY, with 24-hour and historical pricing before you buy.
How to buy Mercury Systems stock in Canada | $66.98
Steps to owning and managing MRCY, with 24-hour and historical pricing before you buy.
How to buy LiveXLive Media stock in Canada | $4.81
Steps to owning and managing LIVX, with 24-hour and historical pricing before you buy.
How to buy Cirrus Logic stock in Canada | $79.51
Steps to owning and managing CRUS, with 24-hour and historical pricing before you buy.